Popular
S&P 500 Breaking Out Again: What This Means...
Questcorp Mining Taps National Inflation Association for Marketing...
Anteros Metals Initiates Channel Sampling at Havens Steady...
Allied Critical Metals Launches Allied USA to Expand...
Radiopharm Theranostics Receives IND approval from US FDA...
Crypto Market Update: Americans Still Uninterested in Crypto...
S&P 500 Breaking Out Again: What This Means...
S&P 500 Breaking Out Again: What This Means...
Chart Mania – 23 ATR Move in QQQ...
NextSource Materials
  • Home
HotInvestingPilots.com
  • Politics
  • World News
  • Stock
  • Investing
Politics

JUST IN: FDA Authorizes Pfizer Antiviral Pill for COVID-19 Home Treatment

by December 22, 2021
written by December 22, 2021

The U.S. Food and Drug Administration issued an emergency use authorization for Pfizer’s antiviral pill for the treatment of mild-to-moderate COVID-19 infection on Wednesday.

“Today’s authorization introduces the first treatment for COVID-19 that is in the form of a pill that is taken orally — a major step forward in the fight against this global pandemic. This authorization provides a new tool to combat COVID-19 at a crucial time in the pandemic as new variants emerge and promises to make antiviral treatment more accessible to patients who are at high risk for progression to severe COVID-19,” said  Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research.

Pfizer’s Paxlovid becomes the first US authorized home COVID-19 treatment. The drug, Paxlovid, is a faster, cheaper way to treat early COVID-19 infections, though initial supplies will be extremely limited, Newsmax reported.

According to its press release, Paxlovid significantly reduced the proportion of people with COVID-19 related hospitalization or death from any cause by 88%.

More from FDA Press Release:

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms or about 88 pounds) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Paxlovid is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset.

Paxlovid is not authorized for the pre-exposure or post-exposure prevention of COVID-19 or for initiation of treatment in those requiring hospitalization due to severe or critical COVID-19. Paxlovid is not a substitute for vaccination in individuals for whom COVID-19 vaccination and a booster dose are recommended. The FDA has approved one vaccine and authorized others to prevent COVID-19 and serious clinical outcomes associated with a COVID-19 infection, including hospitalization and death. The FDA urges the public to get vaccinated and receive a booster if eligible. Learn more about FDA-approved or -authorized COVID-19 vaccines.

Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations. Paxlovid is administered as three tablets (two tablets of nirmatrelvir and one tablet of ritonavir) taken together orally twice daily for five days, for a total of 30 tablets. Paxlovid is not authorized for use for longer than five consecutive days.

Read more here.

An antiviral pill from Merck & Co. also is expected soon to be authorized for COVID-19 treatment.

Aside from the two pills mentioned above, Ivermectin is believed to be a treatment for COVID-19 based on testimonies from professional doctors, nurses, and COVID-19 patients. The Gateway Pundit previously reported that a new international report of 64 studies shows Ivermectin has an 86% success rate as prophylaxis and a 67% success rate in the early treatment of coronavirus.

Two Oklahoma doctors, Dr. John Sutton and Dr. David Jayne also shared their success stories about the use of Ivermectin as a treatment for their patients with COVID-19 in nursing homes.

Highly popular podcast host Joe Rogan said he recovered in 3 days after taking monoclonal antibodies, Ivermectin, Z-pak, prednisone, IV vitamin drip.

Even our contributor Wayne Root, beat the COVID-19 in 48 hours with Ivermectin, just like Joe Rogan.

Uttar Pradesh in India and Indonesia started to see COVID-19 cases fall precipitously after its government granted the Emergency Use Authorization for Ivermectin as the therapeutic drug to cure the Covid-19. You can read more of this story here and here.

 

 

 

The post JUST IN: FDA Authorizes Pfizer Antiviral Pill for COVID-19 Home Treatment appeared first on The Gateway Pundit.

0 comment
0
FacebookTwitterPinterestEmail

previous post
RINOs PANIC as Poll Shows President Trump with a HUGE Lead Among Republicans in 2024 Presidential Race
next post
“Gifts Are Being Delivered, Shelves Are Not Empty” – Biden Absurdly Claims Supply Chain Crisis “Didn’t Actually Occur” (VIDEO)

Related Articles

Early voting in Wisconsin slowed by label printing...

October 24, 2024

American creating deepfakes targeting Harris works with Russian...

October 24, 2024

A GOP operative accused a monastery of voter...

October 24, 2024

Tucker Carlson says father Trump will give ‘spanking’...

October 24, 2024

Trump’s exaggerated claim that Pennsylvania has 500,000 fracking...

October 24, 2024

Biden spurs controversy by saying ‘We’ve got to...

October 23, 2024

McDonald’s where Trump served fries hit with flurry...

October 23, 2024

In close race that could tip House, candidates...

October 23, 2024

As Democratic icons stump for Harris, GOP elders...

October 23, 2024

Past Trump advisers say he’s fascist. Trump says...

October 23, 2024

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

Recent Posts

  • S&P 500 Breaking Out Again: What This Means for Your Portfolio

    July 28, 2025
  • Questcorp Mining Taps National Inflation Association for Marketing & Investor Outreach Campaign

    July 28, 2025
  • Anteros Metals Initiates Channel Sampling at Havens Steady Following Grant Confirmation and Exploration Permit Approval

    July 28, 2025
  • Allied Critical Metals Launches Allied USA to Expand Tungsten Import and Distribution Operations, Lists on OTCQB, and Receives DTC Eligibility

    July 28, 2025
  • Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart

    July 28, 2025
  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 hotinvestingpilots.com | All Rights Reserved

HotInvestingPilots.com
  • Politics
  • World News
  • Stock
  • Investing